Over the last 7 days, the United States market has dropped 1.4%, though it remains up 17% over the past year with earnings forecast to grow by 18% annually. Investing in penny stocks, a term that may seem outdated but still holds relevance, can offer unique growth opportunities typically found in smaller or newer companies. By focusing on those with strong financial health and solid fundamentals, investors might uncover hidden gems that align well with current market conditions.

Let's dive into some prime choices out of the screener.

AlTi Global (ALTI)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: AlTi Global, Inc. is a company that offers wealth and asset management services across various international locations, with a market cap of $520.10 million.

Operations: The company generates its revenue primarily from its Wealth & Capital Solutions segment, which accounts for $270.97 million.

Market Cap: $520.1M

AlTi Global, Inc., with a market cap of US$520.10 million, is experiencing financial challenges typical of penny stocks. The company's short-term assets exceed its short-term liabilities by US$10.1 million but fall short in covering long-term liabilities by US$51.6 million. Despite being unprofitable and having increased losses over the past five years, AlTi has sufficient cash runway for 1.7 years if free cash flow continues to decrease at historical rates. Recent developments include the appointment of Patrick Keenan as CFO and the deployment of Nevis AI platform to enhance operational efficiency in wealth management services.

Oramed Pharmaceuticals (ORMP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Oramed Pharmaceuticals Inc. focuses on the research and development of pharmaceutical solutions using a technology platform for oral delivery of therapeutic proteins, with a market cap of $164.93 million.

Operations: Currently, Oramed Pharmaceuticals Inc. does not report any revenue segments.

Market Cap: $164.93M

Oramed Pharmaceuticals Inc., with a market cap of US$164.93 million, is a pre-revenue company in the biotech sector, focusing on oral delivery technology for therapeutic proteins. Despite lacking significant revenue streams, Oramed has demonstrated strong financial health with short-term assets of US$68.2 million exceeding both short-term and long-term liabilities. The company recently achieved profitability, reporting net income of US$38.31 million for Q1 2026 compared to a loss last year. Oramed's addition to multiple Russell indices highlights its growing market presence, while its debt-free status and high return on equity (46.2%) underscore solid financial management.

Cerus (CERS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cerus Corporation is a biomedical products company with a market cap of $627.15 million.

Operations: The company's revenue is primarily derived from its Blood Safety segment, totaling $216.56 million.

Market Cap: $627.15M

Cerus Corporation, with a market cap of US$627.15 million, has shown significant growth in its Blood Safety segment, generating US$216.56 million in revenue. Recent inclusion in the S&P Healthcare Equipment Select Industry Index and a new debt facility with MidCap Financial provide financial flexibility and reduced interest expenses by up to US$3.5 million annually. Despite being unprofitable, Cerus has reduced losses over five years at 28.2% annually and forecasts earnings growth of 94.61% per year. The company's short-term assets exceed liabilities, but an increased debt-to-equity ratio from 69.7% to 124.2% warrants caution for investors seeking stability in penny stocks.

Key Takeaways

• Discover the full array of 324 US Penny Stocks right here.
• Ready For A Different Approach? We've found 10 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.